Cannabidiol (CBD) end products are becoming increasingly abundant, and the future market development prospects are broad

Cannabidiol (CBD) is the main chemical component and non-addictive component of industrial hemp. Cannabidiol is mainly extracted from cannabis plants. It appears as white to light yellow resin or crystals. It is almost insoluble in water and soluble in organic solvents such as ethanol, methanol, ether, benzene, and chloroform. Cannabidiol has functions such as bactericidal, analgesic, anti-inflammatory, antioxidant, and anti-anxiety. It has rich downstream application scenarios and its main value is reflected in medical treatment.

Cannabidiol is a non-psychoactive compound and is not included in the schedule of the international anti-drug convention and the Chinese Narcotic Drugs Catalog. Globally, the cannabidiol market is mainly concentrated in North America, Europe and the Asia-Pacific region, with North America being the largest market. In terms of market supply, the main manufacturers of cannabidiol and derivatives include Charlotte’s Web, CV Sciences, Elixinol Global, Dixie Brands, Canopy Growth Corporation, etc.

According to the “2022-2027 Cannabidiol (CBD) Industry Market In-depth Research and Investment Prospects Forecast Analysis Report released by the Industrial Research Center ” shows that as the research on industrial hemp continues to deepen, the commercial value of cannabidiol has attracted widespread attention from major companies. Taking advantage of the international cannabis reform, cannabidiol has gradually developed around the world, and a series of products have also been derived based on cannabidiol. Products, including cannabidiol oil, cannabidiol beverages, cannabidiol oral solutions, cannabidiol capsules, cannabidiol skin care products, cannabidiol food, cannabidiol pet supplies, etc. Cannabidiol has broad growth potential, end products are increasingly abundant, and the industry has broad room for future development.

Cannabidiol oral solution (Epidiolex) is a liquid solution that was the first FDA-approved treatment for seizures associated with Dravet syndrome. In 2020, Epidiolex indication was expanded to include seizures associated with tuberous sclerosis TSC. . Epidiolex has been launched and fully reimbursed in the UK, Germany, Italy, Spain and other regions. According to Jazz Pharmaceuticals data, in 2021, Epidiolex product net sales were US$464 million. In the first quarter of 2022, Epidiolex product net sales were US$464 million. $158 million.

In recent years, many countries around the world, including Germany, Australia, Israel, and South Korea, have begun trials to fully legalize medical marijuana. Compared with the international market, due to policy restrictions, my country’s cannabidiol and derivatives market is smaller, and there are fewer products with cannabidiol as a selling point. However, under the trend of globalization, cannabidiol is attracting the attention of more and more consumers with its unique advantages and sources.

Industrial cannabidiol production processes include plant extraction and chemical synthesis. The main purification method is resin adsorption. Industry analysts said that cannabidiol has broad application prospects in food, cosmetics, medicine, pet products and other fields. With the research With continuous deepening and the increase of market layout companies, cannabidiol end products will be more abundant, and the future development prospects of the industry are broad.